 |
市場調査レポート
商品コード
1463455
ヘパリンの世界市場規模、シェア、成長分析、投与経路別、最終用途別 - 産業予測、2024～2031年Global Heparin Market Size, Share, Growth Analysis, By Route of Administration(Intravenous and Subcutaneous), By End Use(Outpatient and Inpatient) - Industry Forecast 2024-2031 |
||||||
| ヘパリンの世界市場規模、シェア、成長分析、投与経路別、最終用途別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月10日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のヘパリンの市場規模は、2022年に74億8,000万米ドルとなり、予測期間（2024～2031年）のCAGRは2.7%で、2023年の76億8,000万米ドルから、2031年までには95億1,000万米ドルに成長する見通しです。
2022年8月、FDAはMomenta Pharmaceuticals, Inc.のM-エノキサパリン製剤を承認しました。MomentaとNovartis AGのジェネリック医薬品子会社であるSandozは、LOVENOXのより技術的に進んだジェネリック医薬品であるM-エノキサパリンを開発しています。M-エノキサパリンは、膝関節置換術や股関節置換術などの整形外科手術の際にも投与されます。最近のヘパリン研究の進歩は、化学療法に使用される超低分子ヘパリンの製造を目指しており、ヘパリン事業に新たな成長の可能性をもたらしています。深部静脈血栓症、肺塞栓症、急性冠症候群、心房細動、人工心肺、心臓手術後の血液濾過など、多くの病気や症状がヘパリンで治療されています。この装置は、膝関節置換術や股関節置換術などの主要な整形外科手術に利用できます。静脈血栓症の頻度は、心血管疾患などの基礎的要因により増加しており、これが世界市場の成長を牽引しています。心臓手術や整形外科手術を受ける患者数の増加や、これらの手術におけるヘパリン使用量の増加により、市場は拡大しています。しかし、ヘパリンによって引き起こされる血小板減少症のような様々な好ましくないヘパリンの副作用が、市場の成長力を制限しています。ヘパリンは動物由来であるため、入手可能性と安全性に大きな懸念があることも制約要因となっています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
ヘパリンの世界市場：投与経路別
- 市場概要
- 静脈内・皮下
ヘパリンの世界市場：最終用途別
- 市場概要
- 外来・入院
ヘパリンの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Pfizer Inc.（United States）
- Sanofi S.A.（France）
- Leo Pharma A/S（Denmark）
- Fresenius Kabi AG（Germany）
- Aspen Holdings（South Africa）
- Teva Pharmaceutical Industries Ltd.（Israel）
- Dr. Reddy's Laboratories Ltd.（India）
- B. Braun Melsungen AG（Germany）
- LEO Pharma A/S（Denmark）
- Baxter International Inc.（United States）
- Shanghai Institute of Biological Products（China）
- Nanjing King-friend Biochemical Pharmaceutical（China）
- Changzhou Qianhong Bio-pharma（China）
- Opocrin S.p.A.（Italy）
- Nantong Pharmaceutical（China）
- Celsus Laboratories Inc.（United States）
- Hebei Changshan Biochemical Pharmaceutical（China）
- Bioiberica S.A.U.（Spain）
- Dongying Tiandong Pharmaceutical（China）
- Shenzhen Hepalink Pharmaceutical Co., Ltd.（China）
- Pharma Action GmbH（Germany）
Global Heparin Market size was valued at USD 7.48 billion in 2022 and is poised to grow from USD 7.68 billion in 2023 to USD 9.51 billion by 2031, at a CAGR of 2.7% during the forecast period (2024-2031).
August 2022 saw the FDA approve Momenta Pharmaceuticals, Inc.'s M-Enoxaparin medicine. Momenta and Sandoz, Novartis AG's generics subsidiary, are developing M-Enoxaparin, a more technologically advanced generic version of lovenox. It is also administered during major orthopedic surgeries like as knee and hip replacements. Recent advancements in heparin research, which aim to manufacture ultra-low molecular weight heparin for use in chemotherapy, have created fresh growth potential for the heparin business. Many illnesses and conditions, including deep vein thrombosis, pulmonary embolism, acute coronary syndrome, atrial fibrillation, cardiopulmonary bypass, and hemofiltration after heart surgery, are treated with heparin. This device can be utilized for major orthopedic procedures, including knee and hip replacements. The frequency of venous thrombosis is increasing due to underlying factors such as cardiovascular sickness, which is driving the global market's growth. The market is expanding due to the rising number of patients undergoing cardiac and orthopaedic surgeries, as well as the growing usage of heparin in these types of surgeries. However, a variety of unfavorable heparin side effects, such as thrombocytopenia brought on by heparin, limit the market's ability to grow. The fact that heparin is derived from animal sources, which raises significant concerns about availability and safety, is another constraining factor.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Heparin Market Segmental Analysis
The type, mode of administration, source, end use, and region of the global heparin market are the segments that make up this market. The market is divided into three types: unfractionated, extremely low weight, and low molecular weight. The market is divided into inpatient and outpatient segments based on end use. The market is divided into intravenous and subcutaneous segments based on the mode of administration. The market is divided into bovine, porcine, and other sources according to source. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.
Drivers of the Global Heparin Market
Venous thromboembolism, or VTE, is more frequent in the elderly but can affect anyone at any age. Heart failure is one of the many illnesses that older individuals are more likely to suffer from than younger people. Heart failure can result in thrombosis. Congestive heart failure is far more common in the elderly, with 85% of heart failure patients being over 65. Atrial fibrillation is three times as common in adults over 80 than in those under 65. These events increase the risk of pulmonary embolism, particularly in older adults. As a result, the requirement for heparin to treat illnesses grows along with the number of elderly individuals, driving up demand for heparin.
Restraints in the Global Heparin Market
The adverse effects of heparin are the primary barriers to market expansion. Bleeding is the most common side effect of heparin. Heparin may cause spontaneous bleeding from the mouth, gums, uterus, stomach, intestines, and open surgical wounds. Heparin may also result in heparin-induced thrombocytopenia (HIT), which increases the risk of bleeding by stimulating the production of antibodies by the immune system against the body's platelets. Therefore, during the forecast period, market expansion may be constrained by the adverse effects of heparin.
Market Trends of the Global Heparin Market
Effective reversal medications are becoming more and more necessary to counteract the anticoagulant effects of heparin and other anticoagulant therapies during surgery or emergency scenarios. In order to give the heparin market another growth path, research and development is now being done on novel anticoagulant reversal medicines.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Heparin Market by Route of Administration
- Market Overview
- Intravenous and Subcutaneous
Global Heparin Market by End Use
- Market Overview
- Outpatient and Inpatient
Global Heparin Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leo Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LEO Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Institute of Biological Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nanjing King-friend Biochemical Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Changzhou Qianhong Bio-pharma (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Opocrin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nantong Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celsus Laboratories Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hebei Changshan Biochemical Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bioiberica S.A.U. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dongying Tiandong Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharma Action GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
